References
- Passamani ER. Cholesterol reduction In coronary artery bypass patients. JAMA 1987: 257(23): 3271–2
- Naito HK, Schwartz CJ. A review of atheroma. In: Naito HK, ed. Nutrition and heart disease. New York: Spectrum Publications. 1982: 1–25
- Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984: 251 (3): 351–64
- Ibid. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984: 251 (3): 365–74
- Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987: 257(23): 3233–40
- Levy RI. Cholesterol and cardiovascular disease: no longer whether, but ratherwhen. In whom, and how? Circulation 1985: 72(4): 686–91
- Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356. 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986: 256(201): 2823–8
- Shucker B, Wittes JT, Culter JA, et al. Changes In physician perspective in cholesterol and heart disease: results from two national surveys. JAMA (in press)
- Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program. NHLBI. C-200. Bethesda, MD 20892
- Hoeg JM, Gregg RE, Brewer HB Jr. An approach to the management of hyperlipoproteinemia. JAMA 1986: 255(4): 512–29
- Bencze WL. Hypolipidemic agents. In: Kritchevsky O, ed. Hypolipidemic agents. (Handbook of experimental pharmacology. Vol 41) New York: Springer-Verlag. 1975: 349–408
- Hunninghake DB, Probstfield JL. Drug treatment of hyperlipoproteinemia. In: Rifkind BM. Levy RI, eds. Hyperlipidemia: diagnosis and therapy. (Clinical cardiology monographs) New York: Grune & Stratton. 1977: 327–62
- NIH Consensus Development Conference Summary. Lowering blood cholesterol to prevent heart disease. JAMA 1985: 253(14): 2080–6
- Kane JP, Malloy MJ, Tun P, et al. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 1981: 304(5): 251–8
- Steinberg D. Studies on the mechanism of action of probucol. Am J Cardiol 1986: 57(16): 16–21H
- Yamamoto A, Takaichi S, Hara H, et al. Probucol prevents lipid storage in macrophages. Atherosclerosis 1986: 62(3): 209–17
- Parthasarathy S, Young SG, Witztum JL, et al. Probucol inhibits oxidative modification of low-density lipoprotein. J Clin Invest 1986: 77(2): 641–4
- Dujovne CA, Krehbiel P, Chernoff SB. Controlled studies of the efficacy and safety of combined probucol- colestipol therapy. Am J Cardiol 1986: 57(16): 36–42H
- Yamamoto A, Matsuzawa Y, Yokoyama S, et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986: 57(16): 29–35H
- Kuo PT, Wilson AC, Kostis JB, et al. Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease. Am J Cardiol 1986: 57(16): 43–8H
- World Health Organization, Committee of Principal Investigators. WHO clofibrate trial: a cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 1978: 40(10): 1069–118
- Lewis JE. Long-term use of gemfibrozil (Lopld) In the treatment of dyslipidemia. Angiology 1982: 33(9): 603–12
- The Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamiilal hypercholesterolemia: a multicenter study. JAMA 1986: 256(20): 2829–34